CINC

AstraZeneca completes acquisition of CinCor Pharma

PremiumThe Fly

2y ago

CinCor Pharma on track to initiate Phase 3 program for baxdrostat in 1H23

PremiumThe Fly

2y ago

AstraZeneca commences tender offer to acquire CinCor Pharma for $26.00 per share

PremiumThe Fly

2y ago

Largest borrow rate increases among liquid names

PremiumThe Fly

2y ago

HUT

SWN

PremiumThe FlyCinCor Pharma downgraded to Equal Weight from Overweight at Barclays

2y ago

Market News

CinCor Surges after Acquisition by AstraZeneca

2y ago

The Fly

AstraZeneca to acquire CinCor Pharma for at least $1.3B

2y ago

CinCor Pharma initiated with an Overweight at Barclays

PremiumThe Fly

2y ago

Jefferies defending CinCor Pharma ‘at zero EV’

PremiumThe Fly

2y ago

CinCor Pharma Shares Plunge after Analyst Downgrade

PremiumMarket News

2y ago

CinCor Pharma downgraded on limited catalysts at Morgan Stanley

PremiumThe Fly

2y ago

PremiumThe FlyCinCor Pharma downgraded to Equal Weight from Overweight at Morgan Stanley

2y ago

The Fly

CinCor downgraded to Perform pending more clarity at Oppenheimer

2y ago

The Fly

CinCor Pharma downgraded to Perform from Outperform at Oppenheimer

2y ago

CinCor Pharma price target lowered to $53 from $73 at Piper Sandler

PremiumThe Fly

2y ago

CinCor Nosedives after Baxdrostat Disappoints in Phase 2

PremiumMarket News

2y ago

CinCor Pharma announces Phase 2 HALO trial does not meet primary endpoint

PremiumThe Fly

2y ago

CinCor Pharma management to meet with Jefferies

PremiumThe Fly

2y ago

PremiumThe FlyCinCor Pharma appoints Kalb as EVP, CFO

2y ago

AMRN

Analysts Pound the Table on These 3 ‘Strong Buy’ Stocks; See Over 70% Upside Potential

Stock Analysis & Ideas

Analysts Pound the Table on These 3 ‘Strong Buy’ Stocks; See Over 70% Upside Potential

2y ago